Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Food Advisory Committee nominations

This article was originally published in The Tan Sheet

Executive Summary

FDA announces two new subcommittees under the FAC - Infant Formula and Nutrition - which have been created "to provide highly specialized expertise in the review and analysis of assigned topics," agency says in Aug. 2 Federal Register notice. Food Advisory Committee was restructured in July 2000 to consist of a "parent" committee and four standing subcommittees (1"The Tan Sheet" July 31, 2000, In Brief). FDA also requests nominations for candidates to fill either current or upcoming committee, subcommittee vacancies...

You may also be interested in...

Food Advisory Committee

FDA requests nominations for candidates to fill either current or upcoming committee vacancies in a July 28 Federal Register notice. In a same-day "Dear Colleague" letter, CFSAN Director Joseph Levitt notes the newly established FAC will consist of a "parent" committee and four standing subcommittees: Dietary Supplements, Additives & Ingredients, Contaminants & Toxicants and Food Biotechnology. The parent committee will be composed of 15 members, including two consumer reps and two non-voting industry reps. Four members will serve as chairs of the subcommittees; each will consist of six standing members serving four-year terms. Six people currently serve on FAC; CFSAN is looking to add up to 29 scientific experts. Nominations can be faxed to FDA at (202) 205-4970

Alvotech And Cipla Expand Biosimilars Deal For Australia And New Zealand

Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.

No Eudamed, No Problem! Latest Guidance Explains Alternatives While Database Is Built

Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts